Kobo Biotech Ltd reported zero revenue and a net loss of ₹4.93 crore for FY24. The company is under Corporate Insolvency Resolution Process, with NCLT approving Beaufond Industries' revival plan.
Kobo Biotech Ltd: Year of Inactivity Amidst Insolvency Proceedings
Kobo Biotech Ltd reported zero total income and a net loss of ₹4.93 crore for the fiscal year 2023-24. The company's earnings per share (EPS) stood at a negative ₹2.07.
Reader Takeaway: Year of no operations, but a potential revival plan approved.
What just happened
Kobo Biotech Ltd recorded nil total income for FY 2023-24, indicating no operational activity. The company continued to post a net loss of ₹4.93 crore. Its Solapur manufacturing facility remained suspended due to financial and regulatory issues. The company has a negative net worth of ₹132.91 crore as of March 31, 2024. Statutory dues payments faced irregularities, and the Board of Directors is suspended, with affairs managed by a Resolution Professional.
Why this matters
The NCLT, Hyderabad Bench, has approved a resolution plan submitted by Beaufond Industries Limited. This plan aims to revive Kobo Biotech as a going concern, subject to the successful implementation of its terms and obtaining necessary regulatory approvals. For shareholders, this plan is the primary avenue for potential value recovery.
The backstory
Kobo Biotech has been admitted into the Corporate Insolvency Resolution Process (CIRP). The company has not conducted manufacturing or commercial activities for FY 2023-24, leading to zero revenue. This prolonged inactivity is attributed to ongoing financial and regulatory challenges.
What changes now
With the NCLT approving Beaufond Industries' resolution plan, there is a pathway for the company's revival. The focus will shift to the implementation of this plan and securing regulatory clearances. The Board's suspension and management by a Resolution Professional indicate a transitional phase.
Risks to watch
Key risks include the successful implementation of the approved resolution plan, obtaining all required regulatory approvals, and addressing the ongoing irregularities in statutory dues. The company's substantial negative net worth also presents a significant financial challenge.
Peer comparison
Information on active peers in a similar business segment or those undergoing insolvency proceedings is not available in the filing.
Context metrics (time-bound)
- FY 2023-24 Total Income: ₹0.02 crore
- FY 2023-24 Net Loss: (₹4.93 crore)
- Net Worth (March 31, 2024): Negative ₹132.91 crore
- NCLT Approval Date: May 11, 2026
What to track next
Investors should monitor the progress of the resolution plan's implementation by Beaufond Industries, any future regulatory approvals, and potential announcements regarding the recommencement of operations or restructuring activities.